Company / Operating Cash Flow per Share
Taysha Gene Therapies, Inc. Operating Cash Flow per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$0.45
FY2025
5-year range
-$3.11 / -$0.39
FY2021-FY2025
Trend
-16.3%
vs FY2024
Sector context
#99 of 212
Health Care
What the data says
At $-0.45, Taysha Gene Therapies, Inc.'s operating cash flow per share ranks #99 of 212 in the Health Care sector. Improved from $-1.40 to $-0.45 over the past 2 years.
Based on SEC 10-K filings.
-0.45 in FY2025.
Improved from $-1.40 to $-0.45 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#99 of 212 in Health CareTop 47% of 212This company -$0.45 Sector average -$14.72
▼
+96.9% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 16.3% year-over-year.
- Ranks #99 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2024.
- Lowest operating cash flow per share in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.45 | -16.3% |
| FY2024 | -$0.39 | +72.1% |
| FY2023 | -$1.40 | +54.0% |
| FY2022 | -$3.04 | +2.1% |
| FY2021 | -$3.11 | -78.7% |
| FY2020 | -$1.74 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026